The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET)

James H. Segars, George A. Hill, Stephanie H. Bryan, Carl M. Herbert, Kevin G. Osteen, B. Jane Rogers, Anne Colston Wentz

Research output: Contribution to journalArticle


The use of gonadotropin releasing hormone agonists (Gn-RHa) has been shown to improve the response in patients classified as "poor responders" undergoing ovarian stimulation for in vitro fertilization/embryo transfer (IVF/ET). This study sought to determine whether GnRHa therapy would benefit patients undergoing IVF/ET who had been classified as "good responders" in prior attempts. Twenty-three patients who had completed a prior IVF/ET attempt but who failed to conceive underwent ovarian stimulation using a combination of GnRHa and human menopausal gonadotropin (hMG). Each patient's prior stimulation served as her control and consisted of clomiphene citrate (CC)/hMG in 18 patients and follicle stimulating hormone (FSH) and/or hMG in 5 patients. The numbers of oocytes retrieved, oocytes fertilized, embryos cleaved, and embryos transferred were all significantly greater in cycles treated with GnRHa/hMG compared to control cycles. The clinical pregnancy rate was 39% and the ongoing pregnancy rate was 26% during the cycle when GnRHa pretreatment was utilized. These data suggest that GnRHa therapy is of benefit even to those patients previously classified as "good responders" undergoing ovarian stimulation for IVF/ET.

Original languageEnglish (US)
Pages (from-to)327-331
Number of pages5
JournalJournal of In Vitro Fertilization and Embryo Transfer
Issue number6
StatePublished - Dec 1 1990



  • gonadotropin releasing hormone (GnRH) agonists
  • in vitro fertilization/embryo transfer
  • ovarian hyperstimulation

ASJC Scopus subject areas

  • Reproductive Medicine
  • Embryology
  • Obstetrics and Gynecology
  • Developmental Biology

Cite this